Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole + famitinib versus standard chemotherapy for ER-high platinum-resistant recurrent ovarian cancer
ChiCTR2600133887Phase 4Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of letrozole and famitinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Xinhua Hospital. Primary endpoint: progression-free survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
letrozolefamitinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600133887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133887.